ResMed Inc (STU:RME)
€ 232.3 -1.9 (-0.81%) Market Cap: 34.52 Bil Enterprise Value: 34.92 Bil PE Ratio: 32.70 PB Ratio: 6.98 GF Score: 98/100

Resmed Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 09:30PM GMT
Release Date Price: €194.04 (+0.39%)
David A. Low
JPMorgan Chase & Co, Research Division - Research Analyst

Music has gone off. So that's my queue. Afternoon, everyone. Welcome back to the afternoon sessions. My name is David Low. I cover health care out of Sydney for JPMorgan. With us this afternoon, we have ResMed, CEO, Mick Farrell. So Mick is going to present for about 20 minutes, and then we'll do 20 minutes of Q&A. A quick reminder, there is the digital conference book if you'd like to ask questions online, but there will also be a mic and it's probably easy to use the mic if you're in the room. Over to you, Mick.

Michael J. Farrell
ResMed Inc. - CEO & Director

Great. Well, thanks, David, and good afternoon all. Go through the disclaimers there from our legal team. So what's ResMed? ResMed is aimed -- ResMed stands for respiratory medicine, but ResMed also stands for residential medicine, treatment and care, where you live and preferably in your own home. And our total addressable market includes our core market of sleep suffocation, as I call it, or sleep apnea as the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot